Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival
复制标题
DOI：
10.1097/jto.0b013e3181b9f236
复制
发表时间：
2009-11-01
影响因子：
20.4
通讯作者：
Kim, Joo Hyun
中科院分区：
文献类型：
--
作者：
Kang, Chang Hyun;Jang, Bo Gun;Kim, Joo Hyun
简介：本研究旨在比较原发性非小细胞肺癌（NSCLC）患者和转移淋巴结患者中切除修复交叉互补组1（ERCC1）、X射线修复交叉互补组1（XRCC1）和β III-微管蛋白的表达谱，并确定每种化疗耐药蛋白的预后意义。材料：符合纳入标准的患者为（1）NSCLC患者，（2）转移淋巴结患者（N1 或 N2），以及（3）接受手术切除后接受铂类辅助化疗的患者。该研究总共纳入了 82 名患者。通过免疫组织化学评估每种蛋白的表达谱，并根据肿瘤位置进行比较。结果：患者的平均年龄为 57.5 +/- 8.4 岁。 N1 患者 30 例，N2 患者 52 例。与原发性肿瘤相比，55% 的转移淋巴结中 ERCC I 表达上调，8% 的转移淋巴结中 ERCC I 表达下调 (p < 0.05)。 XRCC1 也有 56% 的人上调，6% 的人下调（p < 0.05）。然而，β III-微管蛋白在 12% 的患者中上调，在 45% 的患者中下调（p < 0.05）。腺癌患者转移淋巴结中 β III-微管蛋白的表达高于其他细胞类型。转移淋巴结中ERCC1的上调是N1患者的不良预后因素，但对于N2患者则不然。结论：在转移淋巴结中观察到每种蛋白表达谱的显着变化。耐药蛋白引导的治疗应在对原发部位和转移部位的每种蛋白的表达谱进行综合解释后进行。
Introduction: This study aimed to compare the expression profiles of excision repair crosscomplementation group 1 (ERCC1), x-ray repair crosscomplementation group 1 (XRCC1), and beta III-tubulin between patients with primary non-small cell lung cancer (NSCLC) and those with metastatic lymph nodes and to identify the prognostic significance of each chemotherapy resistance protein.Materials: Those who met the inclusion criteria were patients (1) with NSCLC, (2) with metastatic lymph nodes (N1 or N2), and (3) who underwent surgical resection followed by platinum-based adjuvant chemotherapy. A total of 82 patients were included in the study. The expression profile of each protein was evaluated by immunohistochemistry and compared according to tumor location.Results: The mean age of the patients was 57.5 +/- 8.4 years. There were 30 N1 and 52 N2 patients. ERCC I expression was upregulated in 55% and downregulated in 8% of metastatic lymph nodes, when compared with primary tumors (p < 0.05). XRCC1 was also upregulated in 56% and downregulated in 6% (p < 0.05). However, beta III-tubulin was upregulated in 12% and downregulated in 45% of patients (p < 0.05). beta III-tubulin expression in metastatic lymph nodes was greater in patients with adenocarcinoma than other cell types. Upregulation of ERCC1 in metastatic lymph nodes was a poor prognostic factor in N1 patients but not in N2 patients.Conclusions: Significant changes in the expression profile of each protein were observed in metastatic lymph nodes. The resistance protein-guided treatment Should be performed after integrative interpretation of expression profiles of each protein in both primary and metastatic sites.